Advisor Group Holdings, Inc. Atreca, Inc. Transaction History

Advisor Group Holdings, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.13 - $0.38 $394 - $1,152	-3,034 Reduced 46.94%	3,429 $0
Q3 2023 Nov 13, 2023	SELL	$0.26 - $1.12 $2,253 - $9,705	-8,666 Reduced 57.28%	6,463 $1,000
Q2 2023 Aug 10, 2023	SELL	$0.88 - $1.22 $1,974 - $2,737	-2,244 Reduced 12.92%	15,129 $14,000
Q1 2023 May 12, 2023	BUY	$0.91 - $1.82 $1,441 - $2,882	1,584 Added 10.03%	17,373 $19,000
Q4 2022 Feb 10, 2023	BUY	$0.78 - $1.68 $778 - $1,676	998 Added 6.75%	15,789 $12,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $368 - $635	-232 Reduced 1.54%	14,791 $23,000
Q2 2022 Aug 10, 2022	SELL	$1.56 - $3.25 $2,418 - $5,037	-1,550 Reduced 9.35%	15,023 $27,000
Q1 2022 May 04, 2022	BUY	$1.61 - $5.2 $25,995 - $83,959	16,146 Added 3781.26%	16,573 $52,000
Q3 2021 Nov 05, 2021	SELL	$4.91 - $9.07 $1,463 - $2,702	-298 Reduced 41.1%	427 $2,000
Q2 2021 Aug 02, 2021	SELL	$7.82 - $13.8 $1,407 - $2,484	-180 Reduced 19.89%	725 $6,000
Q1 2021 May 13, 2021	BUY	$13.0 - $19.34 $4,251 - $6,324	327 Added 56.57%	905 $14,000
Q4 2020 Feb 10, 2021	BUY	$13.03 - $17.09 $3,322 - $4,357	255 Added 78.95%	578 $10,000
Q3 2020 Nov 12, 2020	BUY	$12.67 - $23.19 $4,092 - $7,490	323 New	323 $4,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.